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Abstract
Background: Considering the advantages of using medicinal herbs as supplementary treatments to sensitize
conventional anti-cancer drugs, studying functional mechanisms and regulatory effects of Echinacea purpurea (as a
non-cannabinoid plant) and Cannabis sativa (as a cannabinoid plant) are timely and required. The potential effects
of such herbs on lung cancer cell growth, apoptosis, cell cycle distribution, cellular reactive oxygen species (ROS)
level, caspase activity and their cannabinomimetic properties on the CB2 receptor are addressed in the current
study.
Methods: The cytotoxic effect of both herb extracts on the growth of lung cancer cells (A549) was assessed using
the MTT assay. The annexin-V-FITC staining and propidium iodide (PI) staining methods were applied for the
detection of apoptosis and cell cycle distribution using flow cytometry. The cellular level of ROS was measured
using 7′-dichlorofluorescin diacetate (DCFH-DA) as a fluorescent probe in flow cytometry. The caspase 3 activity was
assessed using a colorimetric assay Kit.
Results: Echinacea purpurea (EP) root extract induced a considerable decrease in A549 viable cells, showing a time
and dose-dependent response. The cell toxicity of EP was accompanied by induction of early apoptosis and cell
accumulation at the sub G1 phase of the cell cycle. The elevation of cellular ROS level and caspase 3 activity
indicate ROS-induced caspase-dependent apoptosis following the treatment of A549 cells by EP extract. The
observed effects of EP extract on A549 growth and death were abrogated following blockage of CB2 using AM630,
a specific antagonist of the CB2 receptor. Increasing concentrations of Cannabis sativa (CS) induced A549 cell death
in a time-dependent manner, followed by induction of early apoptosis, cell cycle arrest at sub G1 phase, elevation
of ROS level, and activation of caspase 3. The CB2 blockage caused attenuation of CS effects on A549 cell death
which revealed consistency with the effects of EP extract on A549 cells.
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Conclusions: The pro-apoptotic effects of EP and CS extracts on A549 cells and their possible regulatory role of
CB2 activity might be attributed to metabolites of both herbs. These effects deserve receiving more attention as
alternative anti-cancer agents.
Keywords: Echinaceae purpurea, Phyto cannabinoids, Cannabis sativa, Cannabinoid receptor 2, Apoptosis, Cell
cycle, Reactive oxygen species, Caspase 3
Background
The endocannabinoid system (ECS) is an extensive lipid
signaling complex system that is involved in regulating
numerous physiological mechanisms and pathological
processes in the human body [1]. This system consists of
cannabinoid receptors, eicosanoid compounds called
endogenous cannabinoids or endocannabinoids, and
enzymes that synthesize and break down these com-
pounds [2]. The cannabinoid receptors, members of the
rhodopsin-like G-protein coupled receptor (GPCR) fam-
ily, mediate the biological effects of cannabinoids.
Cannabinoids are terpenoid lipid-based chemicals iso-
lated from Cannabissativa (Marijuana) which has been
proven to exert its effects by specific binding to canna-
binoid receptors [3]. Both cannabinoid receptors and
naturally occurring cannabinoids, known as phytocanna-
binoids, have potential therapeutic applications based on
their pivotal roles in regulating immunologic responses,
alleviating inflammation, tumor cell proliferation, angio-
genesis, invasion, and migration [4–7].
Related to this, current antitumor agents and cytotoxic
drugs are not sufficiently effective due to aberrant signal
transduction and resistance in lung cancer cells, There-
fore, the development of new complementary agents for
the treatment of lung cancer patients is needed and ne-
cessary [8].
Interestingly, it was shown that the cannabinoid recep-
tor 2 (CB2) was overexpressed in patients with non-
small cell lung cancer (NSCLC) and tumor growth and
lung metastasis was remarkably inhibited by CB2 ago-
nists [9]. Also, it was revealed that activation of CB2 by
JWH-133 inhibits epithelial to mesenchymal progres-
sion, which leads to suppression of tumor growth in
NSCLC [10]. Another study [11] found that JWH-015, a
CB2 agonist, could inhibit EGFR (Epidermal growth fac-
tor receptor), FAK (Focal adhesion kinase), VCAM1
(Vascular cell adhesion protein 1), and MMP2 (Matrix
metallopeptidases2) pathways and prevent the accumula-
tion of tumor-associated macrophages (TAMs) and con-
trol NSCLC lung cancer cells invasion. Also, drug-
therapeutic compounds, including cannabinoids, can be
transferred to lung cancer cells by inhalation with min-
imal side effects, using high-energy electron-dispersing
nanoparticles, to induce cell death [12]. Recent studies
have shown that cannabis derivatives suppress epidermal
growth factor (EGF) and its downstream pathways in
human lung cancer cells that cause blockage of tumor
cell proliferation and migration [13]. Moreover, Echin-
acea purpurea (EP), known as coneflower, belongs to
the Asteraceae family and exerts immune-modulation,
anti-inflammation, anti-mutagenicity, anti-bacterial,
anti-viral, larvicidal, and psychoactivity features [14]. EP
can prevent virus-induced bacterial adhesion to epithe-
lial cells and reduce the risk of respiratory inflammation
and infection [15, 16]. EP modulates cytokine secretion
and attenuates the clinical symptoms in mice infected by
influenza [17]. Moreover, EP-isolated polysaccharides
modulate the anti-tumor activity of cyclophosphamide
that may be induced in mice transplanted with lung car-
cinoma [18]. Effects of EP can be attributed to alka-
mides, the major constituent of EP that have similar
characteristics as cannabinoids [19, 20]. Due to this
structural similarity, alkamides mimic cannabinoids and
bind to cannabinoid receptors, especially CB2, then sub-
sequently trigger the same pathways and immunologic
reactions as cannabinoids do [2, 21]. Both EP root and
Cannabis sativa, an ancient medicinal plant that con-
tains phytocannabinoids, may play a crucial role in the
pathophysiology of lung cancer, but the effects of these
herbals on cancer cell growth and mechanisms of death
have not been adequately addressed. In this study, we
aimed to investigate the impacts of EP root and Canna-
bis sativa (CS) flower ethanolic extracts, on A549 lung
cancer cells. We clarify and compare their possible ef-
fects on cell viability, rate of apoptosis, cell cycle distri-
bution, level of ROSand caspase 3 activities. The CB2
antagonist AM630 was applied to delineate whether the
observed effects happened in a CB2- dependent manner.
Methods
Chemicals and reagents
DMEM (Dulbecco’s Modified Eagle Medium) high glu-
cose, trypsin/EDTA, NaCl/Pi, penicillin, and strepto-
mycin were obtained from Gibco (Rockville, USA). The
annexin-V-fluorescein isothiocyanate (annexin-V-FITC)
apoptosis detection kit, propidium iodide (PI), 3-(4,5-
dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), dimethyl sulfoxide (DMSO) was purchased from
Sigma Aldrich (Munich, Germany). The caspase 3 col-
orimetric assay kit was obtained from Bio Vision (CA,
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USA). Fluorescent Reactive Oxygen Species (ROS) de-
tection kit was obtained from Marker Gene Technolo-
gies (MGT, USA). The 6-iodopravadoline (AM630) was
purchased from Tocris (Bristol, UK).
EP and CS extracts preparation
The extracts of Echinacea purpurea (EP) root and Can-
nabis sativa (CS) female flower was prepared by the Me-
dicinal Plants Research Center, Faculty of Pharmacy,
Tehran University of Medical Sciences, Tehran, Iran.
The specimens were identified by Dr. Gholam Reza
Amin and deposited at the herbarium of the of Faculty
of Pharmacy, Tehran University of Medical Sciences
(Cannabis sativa: pmp-1378 and Echinacea purpurea:
pmp-1222). Briefly, 100 g of EP roots and the flowering
part of female CS flower, respectively and separately,
were crushed and extracted using a maceration method
(3 × 48 h). Dichloromethane was used to extract EP root
and aqueous methanol (80%) applied for extraction of
CS female flowers. The obtained extracts were concen-
trated and freeze dried to powders and kept at 4 °C until
examination.
Cell culture
The human lung cancer cell line A549 and the human
normal lung fibroblast-like cell line, MRC-5 were ob-
tained from the Pasture Institute of Iran. A549 Cells
were cultured and nourished in a DMEM high glucose
media supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin-streptomycin solution (Pen-Strep),
while EMEM media supplemented with 10% fetal bovine
serum (FBS) was applied for MRC-5 cell culture. Cells
were maintained at 37 °C in 5% CO2 and 100% humidity.
At the confluence of 70–90%, cells were collected by
trypsinization and the collected cells were either used
freshly, or frozen and stored at − 80 °C for subsequent
experiments. Cells were seeded in 96-well plates with a
density of 20,000 cells per well and incubated overnight,
then the medium was replaced with fresh medium con-
taining EP and CS extracts and different concentrations
and CB2 antagonist, and AM-630 for further assays.
Cell viability assay (MTT assay)
The cytotoxic effect of CS and EP extracts, and the ag-
onistic effect of AM630 (6-iodopravadoline) on A549
cells were assessed using MTT colorimetric assay.
Briefly, cells were cultured in 96-well plate with the
density of 20,000 cells/well in DMEM high glucose, sup-
plemented with 10% fetal bovine serum and 1%
penicillin-streptomycin solution, in 5% CO2 at 37 °C.
After being confluent, cells were treated with different
concentrations of CS (50–900 ng/ mL) or EP (50–900
ng/ mL), respectively, and incubated for 24, 36 or 48 h.
AM630 is a proven selective antagonist of CB2 receptor
[22], so cells were co-treated with AM630 in a dose-
dependent manner (10, 25, 50 nM) to clarify its possible
effect on A549 viability. Further, we studied the effect of
AM630 on the CB2 receptor, in the presence of EP or
CS, respectively. Following incubation of A549 with the
various extracts and/or agonist present, 20 mg/mL of 5
mg/ mL MTT solved in PBS was added to each well and
incubated for an extra 4 h at 37 °C. The drug-containing
medium along with MTT was then removed and re-
placed with a 200 mg/ mL of DMSO, which dissolved
the formazan crystals and changed the color of the solu-
tion from colorless/yellow to purple. After 15 min, the
plates were read with a microplate reader (Bio-Rad, CA,
USA) at 570 nm and the data regarding the viability of
the cells in each well was reported as the absorbance
percentage of treated cells via control cells. The experi-
ment was repeated several times and data are represen-
tative of at least three independent experiments and
values are expressed in mean ± standard deviation (SD).
The IC50 values were measured for EP and/or CS at
each time point for both A549 and MRC-5 cells using
nonlinear regression of transformed data. To determine
the selectivity index (SI) which is the criterion indicating
the degree of cytotoxic selectivity and specificity of com-
pound for cancer cells against normal cells, the IC50 of
EP (50–900 ng/ mL) and/or CS (50–900 ng/ mL) ex-
tracts calculated for MRC-5 cells divided by IC50 of
A549 cells at each time point. The SI values more than 2
is considered as high selectivity [23].
Apoptosis assessment
The annexin-V-FITC kit was applied to quantify the per-
centages of apoptotic cells using flow cytometry. Briefly,
A549 cells were treated with (100, 300, or 500 ng/ mL)
of CS and EP extracts, respectively, in the presence or
absence of AM630 (50 nM), then harvested and washed
by PBS. The cell pellets were suspended in 500 μL of 1 ×
binding buffer, 5 μL of annexin-V-FITC, and 5 μL of PI
and incubated for 10 min at room temperature Further,
samples were transferred to FACSCalibur flowcytometry
(Becton Dickinson, SanJose, USA) tube and analyzed
using the supplied software in the instrument.
Cell cycle analysis
The propidium iodide (PI) staining was applied to
analyze the DNA content and cell cycle distribution
using flow cytometry. Cells were treated with CS (100 or
300 ng/ mL) or EP (100 or 300 ng/ mL) with and with-
out AM630 (50 nM) for 36 h and fixed with 70% (v/v)
ice-cold ethanol and washed twice with ice-cold PBS.
The pellets were stained with 0.1 mg/ mL RNase A
(Sigma, Munich, Germany) and 0.05 mg/ mL PI and in-
cubated in the dark, 37 °C for 1 h. The percentages of
cells in each phase of the cell cycle were determined by
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the FACSCalibur flow cytometer (Becton Dickinson,
SanJose, USA) and the inbuilt software (BD Cell Quest
software). The accumulation of cells in the subG1 phase
of the cell cycle is considered as the hallmark of
apoptosis.
Measurement of intracellular reactive oxygen species
(ROS)
The amount of cellular ROS is associated with the inci-
dence of apoptosis, thus the level of ROS following treat-
ment of cells with CS extract (100 or 300 ng/ mL) or EP
(100 or 300 ng/ mL), both with and without AM630 (50
nM) for 36 h, was measured. The 2′,7′-dichlorofluores-
cin diacetate (DCFH-DA) as a fluorescent probe was ap-
plied for the detection of ROS level. DCFH-DA (20 μM
working substrate solution) was added to the cells and
incubated at 37 °C for 45 min before treatment. The level
of generated fluorescence was correlated to the amount
of produced ROS that was detected by FACS Calibur
flow cytometer (Becton Dickinson, SanJose,USA).
Measurement of caspase 3 activity
The level of caspase 3 activity was detected using the
caspase 3 colorimetric assay Kit (Bio Vision, CA, USA).
Cells were treated with CS (100 or 300 ng/ mL) or EP
(100 or 300 ng/ mL) in the presence or absence of
AM630 (50 nM) for 36 h. The cell pellets were lysed by a
cold lysis buffer and incubated for 15 min. The reaction
buffer (50 μM) contained 10 mM dithiothreitol (DTT)
and 5 μM of DEVD conjugated to p-nitroaniline (DEVD-
pNA) substrate (200 μM) and was added to each sample
and incubated for 120min at 37 °C. The caspase 3 activ-
ity was measured at emission wavelength 405 using a
microplate reader.
Statistical analysis
The data analysis and statistical calculations were per-
formed by Graph Pad Prism version 6 (Graph Pad Soft-
ware, San Diego, California). The non-parametric one-
way analysis of variance (ANOVA) with Dennet’s and
Tukey’s post hoc test was used to determine differences
between groups. For determining specificity and accur-
acy, all experiments were implemented in triplicate and
repeated at least three times. Data are presented as
mean ± standard deviation (SD) and differences were
taken significant for P < 0.05, P < 0.01, and P < 0.001.
Statistical differences between different groups in each
graph are marked with an asterisk. The number of aster-
isks indicate the degree of statistical difference and
shown as * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** =
P < 0.0001 in the corresponding figures.
Results
EP extract induced the time and dose-dependent cell
death in A549 cells
To determine the possible effect of EP extract on human
lung cancer cell growth, A549 cells were incubated with
EP extract (50–900 ng/mL) for 24, 36, and 48 h, and the
cell viability was measured using MTT assay. Using EP
extracts, a significant reduction of viable A549 cells was
observed in a dose and time-dependent pattern. (Fig. 1).
After 24 h incubation, the range of 400–900 ng/mLof EP
extract were able to induce cell death, effectively (Fig.
1a). Treatment of A549 cells with 300 or 500 ng/mLof
EP extract for 36 h, reduced cell viability about 20 and
30%, respectively (Fig. 1b). However, the treatment of
A549 cells with 300 or 500 ng/mLof EP extract for 48 h,
resulted in a decrease in cell viability about 30 and 50%,
respectively (Fig. 1c). The respective calculated IC50 (the
half-maximal inhibitory concentration) of EP extract fol-
lowing 24, 36- and 48-h incubation were 1.78, 1.19, and
0.51 μg/mL. Based on data, treatment of MRC-5 cells
with 50–900 ng/mL of EP extract exhibited no signifi-
cant reduction in the percentages of viable cells and the
maximum reduction in the cell viability percentage was
less than 10% (900 ng/mL treatment for 48 h) with the
IC50 value of 8.24, 5.71 and 4.62 μg/mL after 24, 36-
and 48-h incubation with EP (50–900 ng/mL). The SI
values calculated for EP extract was 4.61, 4.79 and 9.05
for 24, 36 and 48 h incubation, respectively which indi-
cated the high selectivity of EP for lung cancer cells ver-
sus lung normal cells (SI > 2 indicate high selectivity).
To determine the possible involvement of CB2 receptor
in EP extract-induced cell death, cells were pretreated
with 10, 25, and 50 nM of AM630 for 30 min before
treatment with 300 ng/mLof EP extract for 36 h. It was
shown that pretreatment with AM630, reverses the cyto-
toxic effect of EP extract on A549 cells significantly as it
is shown in Fig. 1d.
CS extract induced cell death in A549 cells in a time and
dose-dependent manner
The impact of CS on the viability of human lung cancer
cells was measured following treatment of cells with CS
(50–900 ng/mL) for 24, 36, and 48 h. CS induced a sig-
nificant reduction in the percentages of viable cells at
the CS-concentrations of 400 to 900 ng/mLfollowing 24
h incubation (Fig. 2a). It was observed that after 36 h in-
cubation, the concentrations of 300 and 500 ng/mLof CS
induced a decrease in the rate of viable cells, 15 and
25%, respectively (Fig. 2b). CS-concentrations of 300 and
500 ng/mL, after 48 h incubation, induced a decrease in
cell viability about 25 and 45%, respectively (Fig. 2c).
The calculated IC50 of CS extract following 24, 36 and
48 h incubation was 2.28, 1.19, and 0.69 μg/mL, respect-
ively. According to SI value calculation, our data
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revealed the SI values of 3.49, 4.67 and 6.75 for 24, 36
and 48 h incubation of A549 or MRC-5 cells with CS ex-
tracts, respectively. Our data revealed high selectivity of
CS extract for lung cancer cells versus lung normal cells
(SI > 2 indicate high selectivity). The cytotoxic effect of
CS extract (50–900 ng/mL) on MRC-5 cells after 24, 36
and 48 h incubation were not significant and the max-
imum decrease in the percentage of viable MRC-5 cells
was less than 10%. The IC50 values of 7.97, 5.56 and
4.66 μg/mL after 24, 36- and 48-h incubation of MRC-5
cells with CS (50–900 ng/mL) were obtained. We hy-
pothesized that the CS activity was modulated through
CB receptors. To clarify the role of CB2 receptor, cells
were pre-treated with AM630 and incubated with CS for
36 h. We found that reduced cell viability was induced
by 300 ng/mLof CS, and was abrogated following block-
age of the CB2 receptor by AM 630, at 25 and 50 ng/mL
(Fig. 2d).
EP and CS extracts induced apoptosis in human lung
cancer cells
To determine whether the cytotoxic effect of EP and CS
on A549 cells was correlated with the induction of apop-
tosis, the annexin-V and PI double staining method was
applied. Cells were exposed to EP extract at 100, 300,
and 500 ng/mLfor 36 h, then analyzed by flow cytometry.
The annexin-V positive, PI negative cells were early
apoptotic cells (Fig. 3a, and c, respectively). The
Fig. 1 The cytotoxic effects of EP root extract on human lung cancer cells. A549 cells were exposed to different concentrations of EP extract (50–
900 ng/mL) for 24 (a), 36 (b) and 48 (c) h. The percentages of viable cells were determined using MTT assay. Treatment with increasing
concentrations of EP extract induced a time and dose dependent pattern of cell death in A549 cells. Pre-treatment with 10, 25 and 50 ng/mL of
the CB2 antagonist (AM630) attenuated cell death significantly (d). Data represent mean ± SD of three separate experiments. The statistical
differences between treated and untreated groups were analyzed by ANOVA and are indicated by asterisks (* = P < 0.05, ** = P < 0.01,
*** = P < 0.001, **** = P < 0.0001)
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percentage of early apoptotic cells increased with in-
creasing concentrations of EP extract, compared to
the un-treated A549 cells (Fig. 3b), but was reduced
following pre-treatment with AM630 in cell cultures
of EP 300 ng/mL (P < 0.01). Moreover, the treatment
of A549 cells with 100, 300, and 500 ng/mLof CS ex-
tract for 36 h enhanced the rate of early apoptotic
cells in a dose-dependent manner compared to the
un-treated A549 cells (Fig. 4d). EP at 100 ng/mLin-
creased the percentage of early apoptotic cells com-
pared to the control cells, but the CS extract at 100
ng/mLfailed to induce apoptosis following 36 h incu-
bation. Pretreatment of A549 cells with AM630 re-
duced the percentage of apoptotic cells exposed to CS
at 300 ng/mL(P < 0.001) (Fig. 3d).
EP and CS extracts induce cell cycle arrest in A549 cells
Accumulation of cells in the subG1 phase of the cell
cycle, cell cycle arrest, is a hallmark of apoptosis. To
study the effect of EP and CS extracts on the pattern of
A549 cell cycle distribution, we incubated cells for 36 h
with 100 and 300 ng/mLof EP and CS extracts, respect-
ively, and analyzed by flow cytometry. The pattern of cell
cycle distribution is shown in Fig. 4a. A549 cells accu-
mulated in the subG1 phase following treatment with
CS at 100 (P < 0.05) and 300 ng/mL (P < 0.001), com-
pared to the untreated cells (Fig. 4b). In cell cultures ex-
posed to CS at 300 ng/mL, pre-treatment with AM630
reduced the accumulation of cells in the subG1phase
(P < 0.001). Exposure to resulted in increased accumula-
tion of cells in the subG1 phase which was significant at
Fig. 2 The cytotoxic effects of CS extract on human lung cancer cells. A549 cells were treated with different concentrations of CS extract (50–900
ng/mL) for 24 (a), 36 (b) and 48 (c) h and the percentages of viable cells were determined using MTT assay. The time and dose dependent
manner of decreased cell viability is observed following CS treatment. The increasing concentrations of AM630 reduced the rate of cell death
induced by CS extract (d). Data represent mean ± SD of three separate experiments. The statistical differences between treated and untreated
groups were analyzed by ANOVA and are indicated by asterisks (* = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001)
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ET 100 (P < 0.01) and 300 ng/mL (P < 0.001) compared
to the control cells (Fig. 4c). The CB2 antagonist
(AM630) attenuated the effect of EP at 300 ng/mLon the
A549 cell cycle arrest (P < 0.001).
The elevation of ROS level following EP and CS-induced
apoptosis
Elevation of cellular ROS level indicates cell stress and is
accompanied with the induction of apoptosis. The cellu-
lar ROS level was measured in A549 cells following
treatment with 100 and 300 ng/mLof EP and CS extract
for 36 h and analyzed by flow cytometry (Fig. 5a). Data
revealed an elevation in cellular ROS levels following
100 or 300 ng/mLof EP extract exposure, compared to
control cells (P < 0.001) (Fig. 5b). AM630 pre-treatment
attenuated this, i.e. the elevated ROS levels induced by
EP at 300 ng/mL(P < 0.001) (Fig. 4b). CS at 300 ng/
mLalso induced elevation of cellular ROS levels (P <
0.001), compared to the untreated cells. This was abro-
gated with AM630 pre-treatment (P < 0.001) (Fig. 5c).
Lower CS concentrations did not induce increased ROS
levels in A549 cells (Fig. 5c).
The increased activity of caspase 3 toward EP and CS
-elicited apoptosis in lung cancer cells
The possible involvement of caspase 3 as a mediator in
apoptosis execution was assessed with increasing con-
centrations of EP and CS extracts. An increase in cas-
pase 3 activity was detected with EP at 100 (P < 0.05)
and 300 ng/mL (P < 0.007) (Fig. 6a), and CS extract at
Fig. 3 The apoptotic effects of EP and CS extracts on human lung cancer cells. The A549 cells were treated with 100, 300 and 500 ng/mL of EP
and CS extracts separately for 36 h and apoptosis was analyzed by annexin-V and PI staining using flow cytometry. A: represents the flow
cytometry histograms indicating the gating strategy (a), un-treated cells (b), cells treated with 100 ng/mL of EP (c), 300 ng/mL of EP (d), 500 ng/
mL of EP (e) and 300 ng/mL of EP + 50 ng/mL of AM630 (f). B: represents percentages of cells at the early and late apoptosis stages following EP
treatment. C: represents the flow cytometry histograms indicating the gating strategy (a), un-treated cells (b), cells treated with 100 ng/mL of CS
(c), 300 ng/mL of CS (d), 500 ng/mL of CS (e) and 300 ng/mL of CS + 50 ng/mL of AM630 (f). D: represents percentages of cells at the early and
late apoptosis stages following CS treatment. Data represent mean ± SD of three separate experiments. The statistical differences between treated
and untreated groups were analyzed by ANOVA and are indicated by asterisks (* = P < 0.05, ** = P < 0.01, *** = P < 0.001)
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300 ng/mL (P < 0.0073). Lower concentrations of CS did
not change caspase 3 activity, compared to the untreated
cells (Fig. 6b). AM630 attenuated the increased caspase
3 activity induced by EP and CS extracts (P < 0.05),
separately.
Discussion
Lung cancer is one of the deadliest human cancers and
responsible for high rates of cancer related deaths world-
wide. Effective therapeutic approaches is necessary due
to its crippling effects on patient’s lives [8]. The advan-
tages of using medicinal herbs as supplementary treat-
ments along with the common anti-cancer treatments
has received attention recently [24].
The high availability of these medicinal herbs with few
side effects, and the benefit of having several treatment
options make medicinal herbs useful as complementary
drugs that can sensitize conventional medicines [16, 25].
Echinacea purpurea (EP) has attracted attention due to
its wide biological effects to relieve cold symptoms, pain,
seizure, wound healing, and chronic arthritis [26]. The
plant derivatives have a reputation for their immune-
modulating and anti-inflammatory effects since their ad-
ministration enhances immune reactions and suppresses
inflammation using different pathways [16, 27]. In vivo
studies in mouse models showed that EP herb extract oil
causes a decline in the concentration of IL-2, IL-6, and
TNF-alpha and consequently suppresses inflammation
[28]. EP herb extract increased the population of CD49+
and CD19+ lymphocytes in the mice spleen, increased
the cytotoxic activity of natural killer (NK) cells and the
level of interferon-alpha inhibited release of tumor ne-
crosis factor-γ and IL1β and ultimately improved both
innate and adaptive immune responses [29]. Addition-
ally, its cytotoxicity and anti-tumorigenic features pro-
vided interesting evidence, but documentation of a
direct inhibitory effect of EP derivatives on cancer cell
growth is lacking. On the other hand, the remarkable
anti-inflammatory capability of EP derivatives along with
their immune-enhancing features, indicate an efficient
alternative for suppressing tumor growth, stimulating
the immune system, and creating a barrier against tumor
cells. In support of this, this study applied an appropriate
range of EP extract concentrations (50–900 ng/mL), at
different time intervals, to clarify the possible cytotoxic
effect of EP on lung cancer cells. Our data revealed that
EP extract reduced the number of viable lung cancer
cells in a time and dose-dependent manner. The cyto-
toxic effect was accompanied by the induction of apop-
tosis in the A549 cells. To the best of our knowledge,
the relevance of EP extracts in the treatment of the lung
cancer has not been investigated in previous studies, al-
though daily administration of EP results in an increase
in NK cells in the human bone marrow, generating sites
and stimulation of NK cell activity, thereby improving
the functionality of the immune system that may fight
Fig. 4 The effects of EP and CS extracts on cell cycle distribution in human lung cancer cells. The 100 and 300 ng/mL of EP and CS extracts were
exposed to A549 cells for 36 h and cell cycle distribution was analyzed by flow cytometry using PI staining. A: represents the flow cytometry
histograms indicating the un-treated cells (a), cells treated with 100 ng/mL of CS (b), 300 ng/mL of CS (c), 300 ng/mL of CS + 50 ng/mL of AM630
(d), cells treated with 100 ng/mL of EP (e), 300 ng/mL of EP (f), 300 ng/mL of EP + 50 ng/mL of AM630 (g) B: represents percentages of cells at
the different phases of cell cycle following CS treatment. C: represents percentages of cells at the different phases of cell cycle following EP
treatment. Data represent mean ± SD of three separate experiments. The statistical differences between treated and untreated groups were
analyzed by ANOVA and are indicated by asterisks (* = P < 0.05, ** = P < 0.01, *** = P < 0.001)
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cancer cells [30]. EP flower extract and its major deriva-
tive, cichoric acid, induced apoptosis and inhibited
tumor growth via inhibition of telomerase activity in hu-
man colon cancer cells, Caco-2 and HCT-116 cells [31].
Further, EP root extract induced apoptosis via DNA
fragmentation and increased of caspase 3/7 activity in a
dose and time dependent manner in human pancreatic
cancer cells, MIA PaCa-2, and colon cancer cells,
COLO320 [32]. Our data indicate that EP root extract
induces accumulation of A549 cells in the subG1 phase,
Fig. 5 The effects of EP and CS extracts on cellular ROS level in human lung cancer cells. The A549 cells were treated with 100 and 300 ng/mL of
EP and CS extracts, separately, for 36 h and subjected to ROS measurement. A: represents the flow cytometry histograms indicating the un-
treated cells (a), cells treated with 100 ng/mL of EP (b), 300 ng/mL of EP (c), 300 ng/mL of EP + 50 ng/mL of AM630 (d), cells treated with 100 ng/
mL of CS (e), 300 ng/mL of CS (f), and 300 ng/mL of CS + 50 ng/mL of AM630 (g). B: represents the mean level of ROS following EP treatment. C:
represents the mean level of ROS following CS treatment. Data represent mean ± SD of three separate experiments. The statistical differences
between treated and untreated groups were analyzed by ANOVA and are indicated by asterisks (*** = P < 0.001)
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in a dose-dependent manner which accounts as a hall-
mark of apoptosis. Caspase activation is required for the
execution of apoptotic cell death, but apoptosis may also
be induced through a caspase-independent manner [33].
In accordance, the generation of cellular ROS, as inevit-
able byproducts of metabolism, is related to the induc-
tion of caspase activity and mediates apoptotic cell death
[34]. Based on our data, exposure of A549 cells by in-
creasing concentrations of EP root extract resulted in
elevation of cellular ROS. EP extract administration
caused an increase in the caspase 3 activity, indicating
induction of caspase-dependent cell death following EP
extract treatment. EP secondary metabolites such as
alkamides are likely to be responsible for these pharma-
cological effects as they share structural similarity with
cannabinoids components like anandamide [16].
Cannabinoids refer to a group of components with di-
verse biological effects that are mediated through activa-
tion of their specific G-protein-coupled receptors,
namely, CB1 and CB2 [4, 35, 36]. Several cancer-related
properties are attributed to the cannabinoids and their
receptors, including tumor growth suppression, apop-
tosis induction, angiogenesis inhibition, and manipula-
tion cancer related signaling pathways [6, 7]. Cannabis
derivatives and CB receptor activation has been reported
to inhibit tumor growth through a wide range of mecha-
nisms and in various types of tumors including non-
small lung cancer [9], prostate cancer [5], breast cancer
[7], mantle cell lymphoma [37], glioma [38], hepatocarci-
noma [39] and colon cancer [40]. The present study re-
vealed that the CS extract induced lung cancer cell
death in a dose and time-dependent manner. The
cytotoxic effect on A549 cells was accompanied by the
induction of apoptosis and accumulation of cells in the
subG1 phase of the cell cycle. In line with this finding, a
cytotoxic effect of cannabidiol (CBD), the major deriva-
tive of Cannabis, was observed in the MDA-MB-231
breast cancer cell line and colon cancer cells [7, 31]. In
the current study, the increased activity of caspase 3 and
concurrent elevation of cellular ROS level following CS
extract administration, indicate the possible involvement
of ROS in the cannabis-induced caspase-dependent
apoptosis in lung cancer cells. It was shown that, WIN-
55 as a CB receptor agonist induced accumulation of
cells in the sub G1 stage and overstimulation of caspase
3/7 in PC-3 prostate cancer cell lines [37]. Previously re-
ported results were consistent with our observations,
and showed an enhancement in the level of ROS in
breast cancer cells which were induced by Cannabidiol
(CBD) treatment [41]. Constituents of EP and CS herb
plants can stimulate cannabinoid receptors and subse-
quently trigger the same pathways and immunologic re-
actions. Therefore, we assessed the possible role of the
CB2 receptor in the apoptosis-induced effects induced
by EP and CS extracts. M630, a CB2 antagonist, attenu-
ated the rate of cell death, apoptosis, accumulation of
cells in the sub G1 phase, ROS level, and caspase 3 activ-
ity, all induced by both EP and CS extracts in A549 cells.
Based on these observations, the metabolites of EP (alka-
mides) and CS cannabinoids might mediate their effects
through the CB2 receptor in A549 cells. In support of
this, binding of alkamide to the CB2 receptor is required
for the subsequent anti-inflammatory impact of alka-
mide [42]. Additionally, it was shown that the extracted
Fig. 6 The effects of EP and CS extracts on caspase 3 activity in human lung cancer cells. Cells were treated with 100 and 300 ng/mL of EP and
CS extracts for 36 h and the activity of caspase 3 measured accordingly. a: represents the activity of caspase 3 following 100, 300 ng/mL of EP
and 300 ng/mL of EP + 50 ng/mL of AM630 treatment. b: represents the activity of caspase 3 following 100, 300 ng/mL of CS and 300 ng/mL of
CS + 50 ng/mL of AM630 treatment. Data represent Mean ± SD of three separate experiments. The statistical differences between treated and
untreated groups were analyzed by ANOVA and are indicated by asterisks (* = P < 0.05, ** = P < 0.01)
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alkamides from EP root stimulate IL-10 and inhibit
tumor necrosis factor (TNF), and ultimately carry out
the immunomodulatory effects and suppress inflamma-
tion [43]. In conclusion, the pro-apoptotic impact of EP
and CS extracts on lung cancer cells and the modulating
involvement of the CB2 receptor was evaluated. The
cannabinomimetic properties of EP root extract on the
CB2 receptor might be attributed to the alkamides.
These favorable effects of the EP root extract on cell
death, apoptosis, cell cycle distribution, ROS level, and
caspase activity elucidated consistency with the CS men-
tioned effects on the A549 cell line.
Conclusion
Based on the findings, it can be postulated that EP and
CS extracts can inhibit lung cancer cell growth and in-
duce apoptosis and should be considered as an alterna-
tive anti-cancer agent in lung cancer. However, more
research is required to elucidate the detailed underlying
molecular mechanism of action and the exact role of
each derivative of these herbal extracts. Therefore, frac-
tionation of both herbal extracts to purify active com-
pounds and investigating the molecular pathways
influenced by are highly recommended.
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